Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. 4basebio PLC
  6. Summary
    4BB   GB00BMCLYF79

4BASEBIO PLC

(4BB)
  Report
Delayed London Stock Exchange  -  11:35:21 2023-01-27 am EST
735.00 GBX    0.00%
20224basebio Plc - Half-year Report
PR
20224basebio PLC Reports Earnings Results for the Half Year Ended June 30, 2022
CI
20224basebio Plc - Director/PDMR Shareholding
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusFunds 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
735(c) 720(c) 735(c) 735(c) 735(c) Last
2 265 765 0 1 150 1 526 Volume
0.00% -2.04% +2.08% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2022 0,30 M 0,37 M 0,37 M
Net income 2022 -5,20 M -6,44 M -6,44 M
Net cash position 2022 1,10 M 1,36 M 1,36 M
P/E ratio 2022 -17,5x
Yield 2022 -
Sales 2023
Net income 2023
Net Debt 2023
P/E ratio 2023
Yield 2023
Capitalization 90,5 M 112 M 112 M
EV / Sales 2022 298x
EV / Sales 2023
Nbr of Employees 51
Free-Float 37,7%
More Financials
Company
4basebio PLC is a United Kingdom-based specialist life sciences company. The Company is engaged in the design, manufacture and supply of application-specific synthetic deoxyribonucleic (DNA) or messenger ribonucleic acid (mRNA), as well as targeted non-viral vectors for the delivery of nucleic acid payloads. The Company is focused on supplying therapeutic DNA for gene therapies and gene-based vaccines and also... 
Read more
More about the company
Ratings of 4basebio PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about 4BASEBIO PLC
20224basebio Plc - Half-year Report
PR
20224basebio PLC Reports Earnings Results for the Half Year Ended June 30, 2022
CI
20224basebio Plc - Director/PDMR Shareholding
PR
20224basebio Plc - Director/PDMR Shareholding
PR
20224basebio Teams Up With Universities to Research Neurofibromatosis Treatment
MT
20224basebio Plc - Research Collaboration
PR
20224basebio PLC Announces Collaboration with University of Alabama and Teesside University
CI
20224basebio Plc - Result of AGM
PR
20224basebio Plc - Director/PDMR Shareholding
PR
20224basebio Plc - Director/PDMR Shareholding
PR
20224basebio Plc - Final Result and Notice of AGM
PR
20224basebio PLC Reports Earnings Results for the Full Year Ended December 31, 2021
CI
20224basebio Plc - Joint Development Agreement with Heqet Therapeutics
PR
20224basebio PLC Announces Joint Development Agreement with Heqet Therapeutics
CI
20224basebio Plc - Rapidly Produced Customisable Synthetic DNA
PR
More news
News in other languages on 4BASEBIO PLC
20224basebio PLC annonce les résultats de ses bénéfices pour le semestre terminé le 30 juin..
20224basebio PLC annonce une collaboration avec l'Université d'Alabama et l'Université de T..
20224basebio PLC annonce ses résultats pour l'année complète se terminant le 31 décembre 20..
20224basebio PLC annonce un accord de développement conjoint avec Heqet Therapeutics
20224basebio PLC annonce l'élargissement de son offre de produits d'ADN synthétique
More news
Chart 4BASEBIO PLC
Duration : Period :
4basebio PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 735,00 GBX
Average target price 1 200,00 GBX
Spread / Average Target 63,3%
Managers and Directors
Heikki Lanckriet CEO, Executive Director & Chief Scientific Officer
David John Roth Chief Financial Officer & Executive Director
Timothy Paul McCarthy Independent Non-Executive Chairman
Maria del Pilar de la Huerta Martinez Independent Non-Executive Director
Joseph Manuel Fernández Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
4BASEBIO PLC3.52%112
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
SEAGEN INC.8.70%25 936